{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:16:27Z","timestamp":1767179787211,"version":"3.48.0"},"reference-count":32,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aapm.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Applied Clin Med Phys"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose\/objectives<\/jats:title>\n                    <jats:p>Currently, ocular disease is primarily managed with COMS plaque brachytherapy. Various stereotactic radiosurgery (SRS) platforms have also been employed, yet widespread access remains a challenge. Herein, we demonstrate the feasibility of using the HyperArc SRS system to provide an additional platform for the treatment of ocular malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials\/methods<\/jats:title>\n                    <jats:p>Twenty previously treated COMS patients with ocular melanoma were selected for a retrospective HyperArc SRS planning study. The average gross tumor volume (GTV) derived from MRI was 1.19\u00a0\u00b1\u00a00.60 cc. Planning target volumes (PTV) were generated from a 2\u00a0mm expansion of the GTVs. HyperArc plans were created for a TrueBeam LINAC (6MV\u2010FFF) with the Encompass support system and used the AcurosXB algorithm for dose calculation. A dose of 25\u00a0Gy was prescribed to the PTVs and all plans were normalized such that PTVD95%\u00a0=\u00a025\u00a0Gy. All organs at risk (OARs) were spared adequately. Patient\u2010specific quality assurance (QA) and an independent Monte Carlo (MC) second check was performed for all SRS plans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HyperArc plans demonstrated high conformality Paddick conformity index (PCI\u00a0=\u00a00.84\u00a0\u00b1\u00a00.04) with steep dose gradient index (GI\u00a0=\u00a03.29\u00a0\u00b1\u00a00.38). Compared to the HyTEC standard (12.1\u00a0Gy), it adequately spared the optic nerve(s) (\n                      <jats:italic>D<\/jats:italic>\n                      max\u00a0=\u00a07.18\u00a0\u00b1\u00a01.26\u00a0Gy,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Adequate PTV coverage (D99%\u00a0=\u00a023.80\u00a0\u00b1\u00a00.46\u00a0Gy) was achieved with a mean GTV dose of 27.54\u00a0\u00b1\u00a00.47\u00a0Gy. Maximum dose to critical OARs were controlled: brain (6.00\u00a0\u00b1\u00a01.50\u00a0Gy), optic nerve (7.18\u00a0\u00b1\u00a01.26\u00a0Gy), and ipsilateral lens (9.36\u00a0\u00b1\u00a05.67\u00a0Gy). Average beam\u2010on time was under 9 min. End\u2010to\u2010end QA results showed a 99.00\u00a0\u00b1\u00a00.59% pass rate (2%\/2\u00a0mm \u03b3\u2010criteria), with a MC check showing 97.81\u00a0\u00b1\u00a01.24% agreement with the AcurosXB algorithm (2%\/2\u00a0mm).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HyperArc SRS plans provided adequate target coverage, acceptable OARs sparing, and offer a fast, safe, and non\u2010invasive treatment option for ocular tumors. Clinical implementation of this novel methodology is ongoing at our institution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acm2.70399","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:29:41Z","timestamp":1764232181000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of treatment planning with HyperArc stereotactic radiosurgery methods for ocular tumors"],"prefix":"10.1002","volume":"26","author":[{"given":"Chase","family":"Cochran","sequence":"first","affiliation":[{"name":"Medical Physics Graduate Program Department of Radiation Medicine University of Kentucky  Lexington Kentucky USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9300-4857","authenticated-orcid":false,"given":"Shane","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Medical Physics Graduate Program Department of Radiation Medicine University of Kentucky  Lexington Kentucky USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"St. Clair","sequence":"additional","affiliation":[{"name":"Medical Physics Graduate Program Department of Radiation Medicine University of Kentucky  Lexington Kentucky USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-1047","authenticated-orcid":false,"given":"Damodar","family":"Pokhrel","sequence":"additional","affiliation":[{"name":"Medical Physics Graduate Program Department of Radiation Medicine University of Kentucky  Lexington Kentucky USA"},{"name":"Indiana University Health System Department of Radiation Oncology  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203497"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.3805"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro6.1149"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1133909"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942\u2010017\u20100070\u20102"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501971"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3171\/2012.8.GKS121002"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.582"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.12.021"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000534207"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2013.11.008"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1118\/1.4749933"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100869"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.13902"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014\u2010017\u20100948\u2010z"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00483"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014\u2010018\u20100985\u20102"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.06.566"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.13561"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14050937"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194729"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2023.04.013"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.06.038"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.01.053"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3171\/sup.2006.105.7.194"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2000.93.supplement"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mp.16536"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mp.12810"},{"issue":"2","key":"e_1_2_10_30_1","first-page":"135","article-title":"Application of TG\u2010218 action limits to SRS and SBRT pre\u2010treatment patient specific QA","volume":"7","author":"Xia Y","year":"2020","journal-title":"J Radiosurg SBRT"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.13556"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.08.013"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phro.2018.06.001"}],"container-title":["Journal of Applied Clinical Medical Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aapm.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acm2.70399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:12:32Z","timestamp":1767179552000},"score":1,"resource":{"primary":{"URL":"https:\/\/aapm.onlinelibrary.wiley.com\/doi\/10.1002\/acm2.70399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/acm2.70399"],"URL":"https:\/\/doi.org\/10.1002\/acm2.70399","archive":["Portico"],"relation":{},"ISSN":["1526-9914","1526-9914"],"issn-type":[{"type":"print","value":"1526-9914"},{"type":"electronic","value":"1526-9914"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"2025-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70399"}}